OncoZenge - Execution enhanced through expanded Molteni partnership
Impala Nordic comments on OncoZenge AB (publ) (“OncoZenge” or the “Company”) latest news regarding the expanded agreement with its strategic partner Molteni Farmaceutici (“Molteni”), covering commercial-scale manufacturing of BupiZenge™ for Europe.
Under the updated agreement, Molteni assumes responsibility for high-volume, commercial manufacturing of BupiZenge™ for the European market, providing a partner-based route for commercial supply. The expanded agreement shifts much of the operational complexity and uncertainty in manufacturing, quality and logistics to an established European pharmaceutical actor and is consistent with OncoZenge’s capital-light operating model. With key external partners now in place across clinical development and commercial supply, remaining drivers in the investment case are increasingly concentrated to clinical and regulatory outcomes.